Please provide your email address to receive an email when new articles are posted on . The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis. Ryzumvi is expected to be ...
Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...
Please provide your email address to receive an email when new articles are posted on . Significantly more participants treated with phentolamine ophthalmic solution 0.75% vs. placebo achieved ...
FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...
FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...
FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule ...
FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...
Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results